Codexis

• When Scaling up Brings You Down

  By Maxxwell A.R. Chatsko - November 26, 2012 | Tickers: AMRS, CDXS, GEVO, KIOR, SZYM

  Despite sky-high hype before their IPOs and the honeymoon periods shortly thereafter, nearly all sustainable chemical producers trading on the public market are deep in the red today. The capital intensive and headache-filled task of scaling up has been met by Mr. Market’s valuation catapult with a one-way ticket back to reality. Investors who fell to the Siren Song of these greentech IPOs are now (wrongly) questioning the viability more »

• Should your Portfolio have Greentech Stocks?

  By Kevin Gill - August 16, 2012 | Tickers: AMRC, AMRS, CDXS, CVA

  Renewable energy sources will have to replace traditional and non-renewable sources more and more if urbanization and current American lifestyles are to continue, no less the improvement of lifestyles (i.e. increased energy consumption) in emerging countries.

  The wise investor sets aside personal leanings and emotional factors to objectively assess any yield potential from any given form of stock or even a whole sector. Whether or not you’re the more »

• How a Free Codexis Can Elbow its Way to the Top

  By Maxxwell A.R. Chatsko - August 7, 2012 | Tickers: CDXS, CZZ, RDS-A

  On July 16, industrial enzyme developer Codexis (NASDAQ: CDXS) announced that they had signed an Exclusive Negotiation Agreement with long-time financier Royal Dutch Shell (NYSE: RDS-A). Although terms of a new research agreement won’t be finalized until later this month, the announcement has given valuable insight into the future of both companies.

  While everything won’t come up roses for Codexis the company will likely be granted freedom to more »

• Codexis Expands Rolodex

  By Maxxwell A.R. Chatsko - June 8, 2012 | Tickers: ALB, CDXS, RDS-A

  Earlier this week Codexis (NASDAQ: CDXS) announced that the board of directors had completed their search for the company’s next CEO and appointed Albemarle’s (NYSE: ALB) VP of Catalysts John J. Nicols as the new company leader. It was a welcomed move by investors, who responded by lifting shares 10%, but it may only be short-lived as there is still one big question looming overhead.

  The search for more »

• Beware Facebook, Hubris Killed Sustainable Chemicals

  By Maxxwell A.R. Chatsko - May 22, 2012 | Tickers: AMRS, CDXS, FB, KIOR, SZYM |

  A lot of attention has been paid to Facebook’s (NASDAQ: FB) IPO. Is the social media giant overvalued? The answer is clear to Peter Cauwels and Didier Sornette, entrepreneurial risk analysts at the Swiss Federal Institute of Technology Zurich, who have published their detailed valuation tools for social media companies. The duo believes Facebook is really only worth about $30 billion. With overvaluation fresh in mind, I want to more »

• What Does Iogen's Fate Mean for Codexis?

  By Maxxwell A.R. Chatsko - May 8, 2012 | Tickers: CDXS, MRK, RDS-A, SZYM |

  Last week Royal Dutch Shell (NYSE: RDS-A) and industrial enzyme producer Iogen Corporation announced that plans to build a 10 million gallon per year (MMgy) cellulosic ethanol facility in Manitoba, Canada would be suspended. Since 2004 Shell has invested an estimated $500 million into the joint-venture, named Iogen Energy. The most recent agreement began in mid-2010 and was due for reevaluation in 2012 after the proposed process (opens PDF) was more »

• Will Codexis Cash-In on Cellulases?

  By Maxxwell A.R. Chatsko - March 19, 2012 | Tickers: CDXS, DD, NVO, RDS-A, SZYM |

  Today we further explore the importance of enzymes in the sustainable chemicals industry. Codexis (NASDAQ: CDXS) is currently producing CodeXyme™ cellulase enzymes, which they and partner Royal Dutch Shell (NYSE: RDS-A) are hoping can capture a significant share of the $10 billion cellulase market in 2020. There are several reasons to believe the company’s cellulase products will be successful – the most important being its licensed C1 technology.

  The C1 more »

• Five Ways Solazyme Beat 2011

  By Maxxwell A.R. Chatsko - February 28, 2012 | Tickers: AMRS, BG, CDXS, SZYM

  Solzayme (NASDAQ: SZYM), the anointed champion of the sustainable chemicals industry, recently reported earnings for fiscal year 2011. The company demonstrated that making even incremental progress in the sustainable chemicals industry is enough to win the hearts and hard-earned dollars of investors. The company had an impressive 2011 and remains the bright-spot in a gloomy, beaten-down industry. Here are five ways Solazyme beat 2011:

  •  Total revenue for 2011 came in more »

• Energy Common Sense: Codexis Plays the Shell Game With Management

  By Maxxwell A.R. Chatsko - February 22, 2012 | Tickers: CDXS, CZZ, RDS-A

  It's never a good thing for a company to lose two executives in a single month, but that's exactly what has happened at Codexis (NASDAQ: CDXS). Despite the sustainable chemical producer’s successful pharmaceutical enzymes business (fetching $49 million in 2011) and brilliantly orchestrated ascendance to the top of the cellulase enzyme market (in a mere three years) the past month has witnessed the departure of CFO Robert more »

• It's the Feedstock, Stupid: Four Feedstock Plays For the Future of Sugar

  By Maxxwell A.R. Chatsko - February 21, 2012 | Tickers: ADM, BG, CDXS, CZZ, WY

  In the 1992 presidential election, Bill Clinton beat incumbent George Bush Sr. despite his 90% approval rating in March 1991. Once thought a shoe-in for re-election due to an impeccable foreign policy resume (end of Cold War, aiding Kuwait against Saddam), the main reason Bush Sr. fell to Clinton could be summed up in one quote: “It’s the Economy, Stupid”. Similar to the economy’s importance in the 1992 more »

• Obama’s Budget Favors Clean Energy

  By Arthur Pinkasovitch - February 13, 2012 | Tickers: CDXS, FSLR, SI, SO, STP

  President Obama’s budget proposes a radical transformation to the tax code whereby individuals with an annual income of over $1 million would be subjected to a 30% income tax. The tax hike, commonly referred to as the Buffett rule, and the end of tax breaks for oil companies have thus far been the most discussed issues within the outlined budget plan. Allowing the Bush tax cuts to expire, the more »

• Fueling Tomorrow: Codexis

  By Maxxwell A.R. Chatsko - February 13, 2012 | Tickers: AMRS, CDXS, CZZ, PFE, RDS-A

  If you think Solazyme is a tough act to follow, then you certainly aren’t familiar with the next company in the FuelingTomorrow series. Despite being severely underappreciated and undervalued, Codexis Inc. (NASDAQ: CDXS) can hang with the best of ‘em.

  As TheStreet’s Eric Rosenbaum correctly noted, biofuels IPOs may be a worse investment than social media IPOs. However, he incorrectly threw Codexis into the group of unsuccessful biofuels more »